A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI9929 in Adult Subjects with Inadequately Controlled, Severe Asthma
Phase of Trial: Phase II
Latest Information Update: 15 Jul 2017
At a glance
- Drugs Tezepelumab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Acronyms PATHWAY
- Sponsors MedImmune
- 13 Apr 2017 Status changed from active, no longer recruiting to completed.
- 01 Apr 2017 This trial was completed in Bulgaria (end date: 2017-03-01), according to European Clinical Trials Database.
- 19 Mar 2017 This trial has been completed in Lithuania (end date: 1 Mar 2017).